The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced ...

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by ...

Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked ...

Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Despite its well-publicised problems, the FDA is a happy place for ASX biotechs seeking drug or device approvals.